Management of HIV-Infected Patients With ESRD

Advances in Chronic Kidney Disease

Volumn 17, Issue 1, 2010, Pages 102-110

  Novak, James E ^a   Szczech, Lynda A ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Dialysis; ESRD; HIV; Kidney; Transplant

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ANEMIA; HEMODIALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW;

AIDS-ASSOCIATED NEPHROPATHY; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PERITONEAL DIALYSIS; RENAL DIALYSIS; RISK FACTORS;

EID: 71549142575     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2009.08.014     Document Type: Review

References (59)

1. Screening for HIV: recommendation statement. Ann Intern Med 143 (2005) 32-37
2. Mylonakis E., Paliou M., Lally M., et al. Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches. Am J Med 109 (2000) 568-576
3. Vardinon N., Yust I., Katz O., et al. Anti-HIV indeterminate western blot in dialysis patients: a long-term follow-up. Am J Kidney Dis 34 (1999) 146-149
4. Chou C.C., Sun C.Y., and Wu M.S. Human immunodeficiency virus (HIV) infection screening in a dialysis unit. Ren Fail 29 (2007) 459-461
5. Marcus R., Favero M.S., Banerjee S., et al. Prevalence and incidence of human immunodeficiency virus among patients undergoing long-term hemodialysis. The Cooperative Dialysis Study Group. Am J Med 90 (1991) 614-619
6. Rabb H., Agosti S.J., Pollard S., et al. Activated and regulatory T lymphocyte populations in chronic hemodialysis patients. Am J Kidney Dis 24 (1994) 443-452
7. Ahuja T.S., Niaz N., Velasco A., et al. Effect of hemodialysis and antiretroviral therapy on plasma viral load in HIV-1 infected hemodialysis patients. Clin Nephrol 51 (1999) 40-44
8. Celum C.L., Robinson N.J., and Cohen M.S. Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection. J Infect Dis 191 Suppl 1 (2005) S107-S114
9. Kaplan J.E., Masur H., and Holmes K.K. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 51 (2002) 1-52
10. Ahuja T.S., Kumar S., Mansoury H., et al. Hepatitis B vaccination in human immunodeficiency virus-infected adults receiving hemodialysis. Kidney Int 67 (2005) 1136-1141
11. Mandayam S., and Ahuja T.S. Dialyzing a patient with human immunodeficiency virus infection: what a nephrologist needs to know. Am J Nephrol 24 (2004) 511-521
12. Weller I.V., and Williams I.G. ABC of AIDS: Treatment of infections. BMJ 322 (2001) 1350-1354
13. Ahuja T.S., Borucki M., and Grady J. Highly active antiretroviral therapy improves survival of HIV-infected hemodialysis patients. Am J Kidney Dis 36 (2000) 574-580
14. Tourret J., Tostivint I., du Montcel S.T., et al. Outcome and prognosis factors in HIV-infected hemodialysis patients. Clin J Am Soc Nephrol 1 (2006) 1241-1247
15. Rodriguez R.A., Mendelson M., O'Hare A.M., et al. Determinants of survival among HIV-infected chronic dialysis patients. J Am Soc Nephrol 14 (2003) 1307-1313
16. Abbott K.C., Swanson S.J., Agodoa L.Y., et al. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 15 (2004) 1633-1639
17. Hammer S.M., Saag M.S., Schechter M., et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296 (2006) 827-843
18. Kim H.H., and Daar E.S. Newer antiretroviral agents and how to use them. Curr HIV/AIDS Rep 6 (2009) 55-62
19. Havlir D.V., Tierney C., Friedland G.H., et al. In vivo antagonism with zidovudine plus stavudine combination therapy. J Infect Dis 182 (2000) 321-325
20. Ernest II C.S., Hall S.D., and Jones D.R. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312 (2005) 583-591
21. Rao T.K. Human immunodeficiency virus infection in end-stage renal disease patients. Semin Dial 16 (2003) 233-244
22. Gupta S.K., Eustace J.A., Winston J.A., et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 40 (2005) 1559-1585
23. Nettles R.E., Kieffer T.L., Kwon P., et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 293 (2005) 817-829
24. Shrivastava D., Rao T.K., Sinert R., et al. The efficacy of erythropoietin in human immunodeficiency virus-infected end-stage renal disease patients treated by maintenance hemodialysis. Am J Kidney Dis 25 (1995) 904-909
25. Mouthon L., Guillevin L., and Tellier Z. Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia. Autoimmun Rev 4 (2005) 264-269
26. Coyne D.W., Kapoian T., Suki W., et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18 (2007) 975-984
27. Kupka R., Msamanga G.I., Mugusi F., et al. Iron status is an important cause of anemia in HIV-infected Tanzanian women but is not related to accelerated HIV disease progression. J Nutr 137 (2007) 2317-2323
28. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50 (2007) 471-530
29. Abbott K.C., Trespalacios F.C., Agodoa L.Y., et al. HIVAN and medication use in chronic dialysis patients in the United States: Analysis of the USRDS DMMS Wave 2 study. BMC Nephrol 4 (2003) 5
30. Haug C.J., Aukrust P., Haug E., et al. Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab 83 (1998) 3832-3838
31. Cockerell C.J., and Dolan E.T. Widespread cutaneous and systemic calcification (calciphylaxis) in patients with the acquired immunodeficiency syndrome and renal disease. J Am Acad Dermatol 26 (1992) 559-562
32. Wang P.-H., Chu P.-L., Wu C.-C., et al. Calciphylaxis in a continuous ambulatory peritoneal dialysis patient after graft failure of cadaveric kidney transplantation. Acta Nephrol 15 (2001) 77-80
33. Petrosillo N., Puro V., Jagger J., et al. The risks of occupational exposure and infection by human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in the dialysis setting. Italian Multicenter Study on Nosocomial and Occupational Risk of Infections in Dialysis. Am J Infect Control 23 (1995) 278-285
34. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR Recomm Rep 50 (2001) 1-52
35. HIV transmission in a dialysis center-Colombia, 1991-1993. MMWR Morb Mortal Wkly Rep 44 (1995) 404-405 411-402
36. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 50 (2001) 1-43
37. Farzadegan H., Ford D., Malan M., et al. HIV-1 survival kinetics in peritoneal dialysis effluent. Kidney Int 50 (1996) 1659-1662
38. Sreedhara R. Characteristics of peritonitis in HIV-positive PD patients. Semin Dial 13 (2000) 338
39. Tebben J.A., Rigsby M.O., Selwyn P.A., et al. Outcome of HIV infected patients on continuous ambulatory peritoneal dialysis. Kidney Int 44 (1993) 191-198
40. Khanna R., Tachopoulou O.A., Fein P.A., et al. Survival experience of peritoneal dialysis patients with human immunodeficiency virus: a 17-year retrospective study. Adv Perit Dial 21 (2005) 159-163
41. Mitchell D., Krishnasami Z., Young C.J., et al. Arteriovenous access outcomes in haemodialysis patients with HIV infection. Nephrol Dial Transplant 22 (2007) 465-470
42. Brock J.S., Sussman M., Wamsley M., et al. The influence of human immunodeficiency virus infection and intravenous drug abuse on complications of hemodialysis access surgery. J Vasc Surg 16 (1992) 904-910 discussion 911-902
43. Gorski T.F., Gorski Y.C., and Muney J. Complications of hemodialysis access in HIV-positive patients. Am Surg 68 (2002) 1104-1106
44. Schild A.F., Perez E.A., Gillaspie E., et al. Use of the Vectra polyetherurethaneurea graft for dialysis access in HIV-positive patients with end-stage renal disease. Vasc Endovascular Surg 41 (2007) 506-508
45. Mokrzycki M.H., Schroppel B., von Gersdorff G., et al. Tunneled-cuffed catheter associated infections in hemodialysis patients who are seropositive for the human immunodeficiency virus. J Am Soc Nephrol 11 (2000) 2122-2127
46. Schwartz E.J., Fierer D.S., Neumann A.U., et al. HIV-1 dynamics in haemodialysis patients. AIDS 16 (2002) 1301-1303
47. Stock P., Roland M., Carlson L., et al. Solid organ transplantation in HIV-positive patients. Transplant Proc 33 (2001) 3646-3648
48. Sankatsing S.U., Jurriaans S., van Swieten P., et al. Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. AIDS 18 (2004) 1925-1931
49. Sankatsing S.U., Hoggard P.G., Huitema A.D., et al. Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools. Clin Pharmacokinet 43 (2004) 823-832
50. Izzedine H., Launay-Vacher V., Baumelou A., et al. Antiretroviral and immunosuppressive drug-drug interactions: an update. Kidney Int 66 (2004) 532-541
51. Carter J.T., Melcher M.L., Carlson L.L., et al. Thymoglobulin-associated Cd4 + T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant 6 (2006) 753-760
52. Fischereder M., Luckow B., Hocher B., et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 357 (2001) 1758-1761
53. Meanwell N.A., and Kadow J.F. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. Curr Opin Investig Drugs 8 (2007) 669-681
54. Trullas J.C., Cofan F., Cocchi S., et al. Effect of thymoglobulin induction on HIV-infected renal transplant recipients: Differences between HIV-positive and HIV-negative patients. AIDS Res Hum Retroviruses 23 (2007) 1161-1165
55. Roland M.E., Barin B., Carlson L., et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 8 (2008) 355-365
56. Gruber S.A., Doshi M.D., Cincotta E., et al. Preliminary experience with renal transplantation in HIV+ recipients: low acute rejection and infection rates. Transplantation 86 (2008) 269-274
57. Ballarin R., Di Benedetto F., Masetti M., et al. Combined liver-kidney transplantation in an HIV-HCV-coinfected patient with haemophilia. AIDS 22 (2008) 2047-2049
58. Heredia A., Gilliam B., Latinovic O., et al. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother 51 (2007) 2489-2496
59. Samonakis D.N., Cholongitas E., Triantos C.K., et al. Sustained, spontaneous disappearance of serum HCV-RNA under immunosuppression after liver transplantation for HCV cirrhosis. J Hepatol 43 (2005) 1091-1093